CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Evofem Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Evofem Biosciences Inc
12400 High Bluff Drive, Suite 600
Phone: (858) 550-1900p:858 550-1900 SAN DIEGO, CA  92130  United States Ticker: EVFMEVFM
Business Summary
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. It is commercializing advanced products to address unmet needs in women’s sexual and reproductive health. Its first FDA-approved product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Phexxi is an advanced gel that works to prevent pregnancy without the use of hormones. Phexxi prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Phexxi is designed to address underserved and unmet needs in the birth control market. Using its platform, women can have a telehealth visit with a health care provider to determine their eligibility for a Phexxi prescription. It is also focused on commercializing SOLOSEC (secnidazole) 2g oral granules that address two pervasive sexual health infections.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Interim Chairman of the Board of Directors, President, Chief Executive Officer Saundra L.Pelletier 54 4/13/2023 1/17/2018
Chief Financial Officer, Company Secretary IvyZhang 46 4/13/2023 4/13/2023
Independent Director KimKamdar 1/1/2018 4/1/2011
3 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Evofem Biosciences Operations Inc 12400 High Bluff Dr Ste 600 SAN DIEGO CA United States
Evofem Inc 12636 High Bluff Drive, Suite 400 SAN DIEGO CA United States

Business Names
Business Name
EVFM
EVFMD
Evofem Biosciences Operations Inc.
6 additional Business Names available in full report.

General Information
Number of Employees: 37 (As of 3/21/2024)
Outstanding Shares: 100,328,686 (As of 11/8/2024)
Shareholders: 14
Stock Exchange: OTC
Federal Tax Id: 208527075
Fax Number: (302) 636-5454
Email Address: info@neothetics.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024